Welcome to our dedicated page for Inmode Ltd. news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on Inmode Ltd. stock.
InMode Ltd. (INMD) delivers innovative radiofrequency-based solutions for minimally invasive aesthetic treatments. This news hub provides investors and medical professionals with essential updates on the company's strategic developments, technological advancements, and market leadership in medical aesthetics.
Access real-time announcements including quarterly earnings, product launch details, regulatory milestones, and partnership agreements. Our curated collection features press releases covering facial/body contouring innovations, clinical study results, and intellectual property developments central to INMD's growth strategy.
Key updates include FDA-cleared device announcements, global expansion initiatives, and R&D breakthroughs in RF energy applications. Bookmark this page for verified information on corporate governance changes, manufacturing updates, and industry conference participation directly from InMode's communications team.
InMode (NASDAQ: INMD) reported Q3 2025 GAAP revenue of $93.2M, down from $130.2M in Q3 2024 (which included $31.9M of pre-order sales). GAAP and non-GAAP gross margin was 78%. GAAP net income was $21.9M ($0.34 diluted EPS) and non-GAAP net income was $24.5M ($0.38 diluted EPS). Cash and marketable securities totaled $532.3M as of September 30, 2025. Management reaffirmed full‑year 2025 guidance: revenues of $365M–$375M, non‑GAAP gross margin 78%–80%, non‑GAAP operating income $93M–$98M, and non‑GAAP EPS $1.55–$1.59. Company noted cautious consumer demand and named Michael Dennison president of North America.
InMode (Nasdaq: INMD) appointed Michael Dennison as President of North America, effective Nov. 3, 2025. Dennison joins the role after nearly a decade at InMode and promotion from Vice President of Sales. The company said he progressed through roles from District Sales Manager to VP of Sales, driving national revenue growth, expanding market share, and strengthening distribution across North America.
Management said the move is part of a North American restructuring intended to advance strategic initiatives and accelerate growth. Dennison previously held multiple leadership positions at Cynosure and is described as having consistently exceeded sales targets and built high-performing teams.
InMode (Nasdaq: INMD) will participate in three investor conferences in November 2025: the UBS Global Healthcare Conference (in-person one-on-ones, Palm Beach Gardens, FL) on Monday, November 10; the Jefferies Global Healthcare Conference (in-person fireside chat and one-on-ones, London, U.K.) with a fireside chat at 4:00 pm GMT on Tuesday, November 18 and a live webcast available; and the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (in-person one-on-ones, New York, NY) on Thursday, November 20. Presenters include CEO Moshe Mizrahy and CFO Yair Malca.
InMode (Nasdaq: INMD) expects to release Q3 2025 results before market open on Nov 5, 2025 and will host a conference call at 8:30 a.m. ET that day. Management currently expects Q3 revenue of $92.5M–$93.0M, a non-GAAP gross margin of 77%–79%, and reiterated full‑year 2025 revenue guidance of $365M–$375M. Preliminary results exclude share‑based compensation per the company’s non‑GAAP disclosure and remain subject to final adjustments. The company provided webcast, preregistration, and replay details for investors and analysts.
DOMA Perpetual Capital Management, a significant shareholder of InMode Ltd. (NYSE: INMD), has sent a letter to the company's Board of Directors urging for immediate capital return to shareholders. The activist investor is pushing for two major share buybacks: 10% in Q4 2025 and another 10% in Q1 2026.
The letter criticizes InMode's management, highlighting that the company holds 53% of its market cap ($510 million) in cash with no debt, while generating over 10% of its market cap in cash annually. DOMA argues that after subtracting the cash position, InMode trades at just 3x future free cash flow and earnings, representing a severely depressed valuation.
DOMA challenges management's anti-buyback stance and reminds the Board of its legal and fiduciary duties to shareholders, warning of potential legal consequences for failing to act in shareholders' best interests.
InMode (NASDAQ:INMD), a leading provider of innovative medical technologies, has announced its participation in the upcoming Baird 2025 Global Healthcare Conference. The company's CFO Yair Malca will engage in a fireside chat on September 10, 2025, at 8:30 AM ET in New York.
The presentation will be moderated by Baird's Senior Research Analyst Jeff Johnson and will be available via live webcast. Additionally, the company will conduct one-on-one meetings with investors during the conference.
InMode (NASDAQ:INMD), a leading global provider of innovative medical technologies, has announced its participation in two upcoming investor conferences in August 2025. The company will attend the 10th Annual Needham Virtual MedTech & Diagnostics Conference on August 11, where CEO Moshe Mizrahy will conduct virtual one-on-one meetings.
Additionally, CFO Yair Malca will participate in the Canaccord 45th Annual Global Growth Conference in Boston on August 12 at 2:30 pm ET, featuring a fireside chat moderated by Caitlin Cronin and investor meetings. A live webcast of the presentation will be available.
InMode (NASDAQ: INMD) reported its Q2 2025 financial results with quarterly revenues of $95.6 million, up from $86.4 million in Q2 2024. The company maintained strong 80% gross margins and achieved GAAP net income of $26.7 million ($0.42 per diluted share).
Despite macroeconomic headwinds and cautious consumer behavior, InMode's international business, particularly in Europe, showed strong performance. However, the company revised its 2025 guidance downward, now expecting revenues between $365-375 million, compared to previous guidance of $395-405 million.
The company maintains a robust financial position with $510.7 million in total cash and investments. Management noted that U.S. tariffs at 10% are expected to impact gross margins by 2-3%.
InMode (NASDAQ: INMD), a leading medical technology provider, has announced preliminary Q2 2025 financial expectations and revised its full-year guidance. The company expects Q2 2025 revenue between $95.4-$95.5 million with a non-GAAP gross margin of 79-80%.
Due to market weakness and U.S. economic uncertainty, InMode has decreased its full-year 2025 revenue guidance to $365-375 million, down from the previous guidance of $395-405 million. The company will discuss detailed Q2 2025 results in a conference call scheduled for July 30, 2025.
InMode (NASDAQ: INMD) CEO Moshe Mizrahy has responded to concerns raised by DOMA Perpetual Capital Management LLC in a public letter. The response addresses several key issues:
Regarding share buybacks, InMode has repurchased $412M in shares over the past 12 months and $508M in the last 2.5 years, aiming to return capital to shareholders tax-efficiently. On manufacturing, Mizrahy defended keeping production in Israel, citing the company's expertise and need for proximity to R&D teams. He noted successful on-time deliveries to 90 countries despite ongoing regional conflicts.
Addressing North American sales concerns, Mizrahy attributed the business slowdown to macroeconomic factors and financing difficulties for medical equipment rather than organizational issues. He also defended his leadership style against DOMA's criticism, noting his role as co-founder and long-term manager of the company.
FAQ
What is the current stock price of Inmode Ltd. (INMD)?
What is the market cap of Inmode Ltd. (INMD)?
